The Cell and Gene Therapy Catapult is a non-profit organization based in London. It was established in 2012 as an independent center of excellence to advance the growth of the UK cell and gene therapy industry. The organization aims to do this by bridging the gap between scientific research and full-scale commercialization.
Supported by Innovate UK, the organization's mission is to drive the growth of the industry by helping cell and gene therapy organizations across the world translate early stage research into commercially viable and investable therapies. It does that by offering leading-edge capability, technology, and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics, and market access expertise.
In April 2018, the organization opened a cell and gene therapy manufacturing center. Thereafter in September 2018, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued two licenses--a Manufacturing and Importation Authorisation (MIA) and an MIA for investigational medicinal product (MIA IMP)--to the organization for the production commercial medicines for patient use or to support clinical trials.
Dr. Damian Marshall
Director of Industrialization, New and Enabling Technologies
Dr. Jacqueline Barry
Chief Clinical Officer
Dr. Jonathan Appleby
Chief Scientific Officer
Dr. Michael Bennet
Director of Business Development
Dr. Stephen Ward
Chief Manufacturing Officer
Manufacturing Center Director
Director of Industrialization, Manufacturing
Chief Business Officer
MHRA permits cell/gene therapy production at CGT Catapult site